Leading international law firm Herbert Smith Freehills Kramer has advised MMG Limited (01208.HK) on a US$500 million zero coupon convertible bond issue. The bonds were issued on 8 October and listed on the Hong Kong Stock Exchange. The transaction included a concurrent delta placement to hedge investors' market risk. Proceeds will be used to refinance MMG's offshore indebtedness.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by William Ku
Not
In two remarkably similar cases, Re Peking University Founder Group Company Limited [2023] HKCFI 1350 (the "Peking University Case") and Re Tsinghua Unigroup Co., Ltd [2023] HKCFI 1572 (the "Tsinghua Case"), the Hong Kong Court affirmed the enforceability of keepwell deeds entered into by PRC companies as credit enhancement for bonds issued by their respective offshore subsidiaries.
Remed: TP of W40,000
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. We estimate Remed’s 2020 sales at W31.8bn (+71.7% y-y) and OP at W10.1bn (+134.7% y-y; OPM of 31.6%). Its aesthetics division, which supplies key components for Allergan’s new body contouring device CoolTone launched in Sep 2019, booked 2019 sales of W5.9bn. The division’s sales should rise to W17.1bn this year.
Hugel: TP of W480,000
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Hugel completed a permit review for Letybo (BTX) in China in April. Final approval should be received in 3Q20 after supplementary documents are submitted this month.
(2H20 Industry Outlook) Pharmaceutical/Bio: Further Benefits Expected from Global Spread of COVID-19
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. A large number of pharmaceutical/bio players, particularly testing kit companies, have been seeing earnings expansion amid the Covid-19 outbreak. With share prices of related treatment and vaccine providers soaring and new orders at contract manufacturing organization (CMO) players increasing, the Kospi pharmaceuticals index has been outperforming the market by a wide margin in 1H20.
Celltrion Healthcare: On Track for Full-fledged Earnings Growth
The author is an analyst of NH Investment & Securities. She can be reached at william.ku@nhqv.com. -- Ed. Driven by Truxima and Herzuma launches in the US and Remsima SC launches in Europe, Celltrion Healthcare registered a 1Q20 earnings surprise. Backed by operating leverage effects, the firm appears to have entered a structural growth phase. We raise our TP to W110,000 and maintain the company as our top pick for the bio sector.
CKD: Hard to View 1Q20 Results as True Earnings Surprise
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. CKD’s 1Q20 results topped consensus on steady sales growth for prescription drugs (led by treatments for chronic diseases) and reduced SG&A expenses. Needs R&D investments to bear fruit Although adhering to our TP of W100,000, we lower our investment rating on CKD from Buy to Hold. The firm’s sales mix is being worsened by a greater portion of merchandise sales.
Yuhan Co.: Awaiting Appearance of Structural Performance Improvement
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Given the influence of the Covid-19 crisis, we are taking a conservative approach in our operating income estimates for Yuhan. Other than already-expected inflow of licensing fees, the firm currently lacks sources of structural performance growth momentum.
Samsung Biologics: Once Again, Earnings Surprise
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Samsung Biologics’ 1Q20 OP beat consensus by 46.2% thanks to rising utilization rates and reduced SG&A expenses. We raise our TP to reflect revised DCF valuation assumptions. We maintain a Buy rating, as the firm has already reached its annual order target for Plant #3, and expectations for orders for a Covid-19 treatment are valid.
Chong Kun Dang: Expect Solid 1Q20 Results
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Chong Kun Dang (CKD) should feel limited Covid-19 impacts, thanks to its chronic disease-oriented drug portfolio. While we expect CKD’s 1Q20 earnings to show improvement on SG&A expense reduction, we lower our TP in light of declining pharmaceutical sector multiples. Product portfolio relatively less affected by Covid-19 We lower our TP on CKD from W125,000 to W100,000, but maintain a Buy rating.
Dong-A ST: Pay Attention to 2Q20 Earnings
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Dong-A ST’s 1Q20 earnings are expected to show y-y improvement, thanks to supply expansion prior to enforcement of the MFDS’s order to suspend business operations (March-May). However, we anticipate conservative earnings from 2Q20, when the effects of business suspension and Covid-19 should begin to be felt in earnest.
SK Chemicals: 1Q20 preview: Green Chemicals Division Leads Solid Earnings
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. SK Chem has been selected by the Korea Centers for Disease Control & Prevention to be the priority negotiator for a Covid-19 vaccine development project. The firm’s licensing-out deal partner has finished submitting an IND application to conduct global phase-II clinical trials on a next-generational pneumococcal vaccine.
Dongkook Pharm: Shining Value Stock Regardless of Market
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Despite the Covid-19 crisis, we expect Dongkook Pharm’s pharmaceutical business to maintain positive sales growth. Focusing on home-shopping channels, the cosmetics division should see ongoing rapid sales growth as well. Viewing Dongkook Pharm as undervalued from a mid/long-term perspective, we recommend paying attention to the play.
Vaccine Industry: Flowers Blooming amidst Chaos
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. With Covid-19 having entered the global expansion phase, we turn attention to cases of earnings growth at global vaccine makers after the 2009 H1N1 flu epidemic. We advise focusing on leading domestic vaccine makers SK Chem (initiate) and Green Cross (our pharma sector top pick).
Bio Industry: Clinical Trial Update for Gilead's COVID-19 Treatment
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. In addition to a clinical trial of Remdesivir that started in China in February, Gilead has launched additional global phase III clinical trials of the drug. Initial clinical trial results in China should be available this month, with global phase III initial results anticipated in April. Upon confirmation of favorable clinical results, markets should stabilize to some extent.
Celltrion Healthcare: Earnings Uptrend Kicks off
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Celltrion Healthcare registered a 4Q19 earnings surprise, led by: 1) high-margin exports of Truxima and Herzuma to the US; and 2) adjustments to its EU partnership agreement. Considering such, we raise our TP from W67,000 to W85,000. Anticipating strong earnings growth in 2020, we continue to suggest Celltrion Healthcare as our top pick for the bio sector.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with William
Contact William, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack